Home / Healthcare / Radiosurgery Market

Radiosurgery Market Size, Share and Global Trend By Indication (Cobalt 60 Systems (Gamma Knife), Electron-Emitting High-Energy Linear Accelerators(Linac), Proton Beam Therapy), By End User (Hospitals, Clinics, Others) and Regional Forecast, 2024-2032

Report Format: PDF | Published Date: Ongoing | Report ID: FBI101129 | Status : Upcoming

Radiosurgery is a form of surgery performed with the help of radiation, that destructs selected areas of the tissue using radiations. Radiosurgery can be categorized into stereotactic radiosurgery and staged radiosurgery. Stereotactic radiosurgery is performed on the accurate target with the radiation and in case of staged radiosurgery, these surgeries are performed in certain interval of time with smaller doses of radiation.


Radiosurgery is commonly used for the treatment of various type of cancers and tumors. According to the National Cancer Institute (NCI), 50% of the cancer patients are treated with radiosurgery. Radiosurgery includes advanced robotics, tumor tracking and imaging capabilities this makes treatment and surgeries easier for healthcare providers. Elekta AB introduced Leksell Gamma Knife Icon device which had a new concept of treating any target in the brain virtually. This device has capabilities of ultra-precise micro radiosurgery.



High prevalence of cancer and rise in a number of patients with a brain tumor is expected to drive the radiosurgery market growth. A growing number of hospitals and physicians specializing in oncology treatment are adopting radiosurgery techniques due to shorter procedure time. These are some of the factors that are expected to drive the growth of the global electrosurgery market.


However, the high treatment cost and lack of reimbursement policies are some of the major restraining factors for the radiosurgery market  growth in the forecast period.


Key Players Covered


Some of the major companies that are present in the radiosurgery market are Siemens, Varian Medical Systems, Elekta AB, Accuray Incorporated, Ion Beam Applications SA, C.R. Bard, Inc., IsoRay, Inc., Mevion Medical Systems, Inc., and Nordion Inc., NTP, Mallinckrodt Public Limited and others.


SEGMENTATION






















SEGMENTATION


DETAILS

By Indication



· Cobalt 60 Systems (Gamma Knife)


· Electron-Emitting High-Energy Linear Accelerators(Linac)


· Proton Beam Therapy



By End User



· Hospitals


· Clinics


· Others



By Geography



· North America (USA and Canada)


· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


· Latin America (Brazil, Mexico and Rest of Latin America)


· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



 


In 2018, among end user, the hospital segment dominated the radiosurgery market share due to an increase in the number or radiosurgery performed and adoption of new and technologically advanced radiosurgical devices available in the market. This segment is projected to grow at comparatively higher CAGR during the forecast period.


Key Insights



  • Regulatory Scenario, By Key Regions

  • Reimbursement Scenario, By Key Regions

  • Technological Advancements

  • Pricing Analysis, By Treatment Type

  • Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions


Regional Analysis


North America dominated the radiosurgery market in 2018, due to increasing incidence of cancers, growing demand for new and innovative surgical methods for treatment of cancer by healthcare facilities, and rising adoption of new advanced techniques for the treatment of cancer. Europe accounted for the second largest share of the radiosurgery market share in 2018. Higher adoption of advanced techniques in cancer treatment including radiosurgery, in countries such as Germany, U.K., and France, along with the rising incidence of cancers in the region are some of the factors driving the growth of the market in Europe.


Key Industry Developments



  • In December 2017, Xcision Medical Systems, LLC., received U.S. Food and Drug Administration approval for the new noninvasive stereotactic radiotherapy system intended for use in treating cancer in breast tissue.

  • In August 2017, Artemis Hospitals has launched North India’s first M6 Cyberknife Radiosurgery technology as part of its effort to provide precise, painless and non-invasive radiation treatment to thousands of patients seeking treatment of inoperable cancerous and non-cancerous tumours.

  • Global
  • 2023
  • 2019-2022
  • PRICE
  • $ 4850
    $ 5850
    $ 6850
    Pre Book

Healthcare Clients